journal
MENU ▼
Read by QxMD icon Read
search

International Clinical Psychopharmacology

journal
https://www.readbyqxmd.com/read/28492411/advanced-glycation-end-products-among-patients-maintained-on-antipsychotics
#1
Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Karsten Suhre, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Yahya Hani, Reem El Sherbiny, Hassen Al-Amin
The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded...
May 10, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28430670/comparison-between-long-acting-injectable-aripiprazole-versus-paliperidone-palmitate-in-the-treatment-of-schizophrenia-systematic-review-and-indirect-treatment-comparison
#2
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsley
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo...
April 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28383309/utility-of-functioning-in-predicting-costs-of-care-for-patients-with-mood-and-anxiety-disorders-a-prospective-cohort-study
#3
Conal Twomey, Alarcos Cieza, David S Baldwin
Development of payment systems for mental health services has been hindered by limited evidence for the utility of diagnosis or symptoms in predicting costs of care. We investigated the utility of functioning information in predicting costs for patients with mood and anxiety disorders. This was a prospective cohort study involving 102 adult patients attending a tertiary referral specialist clinic for mood and anxiety disorders. The main outcome was total costs, calculated by applying unit costs to healthcare use data...
April 5, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28383308/antidepressant-effect-in-older-depressed-patients-the-lessons-of-two-agomelatine-trials
#4
Guy M Goodwin, Pierre Thomas, Reinhard Heun, Patrice Boyer, Françoise Picarel-Blanchot, Christian de Bodinat
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response...
April 5, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28379882/silexan-in-generalized-anxiety-disorder-investigation-of-the-therapeutic-dosage-range-in-a-pooled-data-set
#5
Siegfried Kasper, Hans-Jürgen Möller, Hans-Peter Volz, Sandra Schläfke, Angelika Dienel
Silexan, a special active substance produced from Lavandula angustifolia, is efficacious in subsyndromal anxiety at a dose of 80 mg/day, but its effective dosage in generalized anxiety disorder (GAD) has yet to be defined. In two double-blind, placebo-controlled trials, daily doses of 10, 40, 80, and 160 mg silexan were administered for 10 weeks. A total of 925 adults with GAD according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria and a Hamilton Anxiety Scale (HAMA) total score of at least 18 points were analyzed for efficacy...
April 4, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28368900/the-effect-of-methylphenidate-on-anxiety-and-depression-symptoms-in-patients-with-asperger-syndrome-and-comorbid-attention-deficit-hyperactivity-disorder
#6
Pavel Golubchik, Michal Rapaport, Abraham Weizman
The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. The severities of ADHD, anxiety, and depression symptoms were assessed by means of the ADHD Rating Scale (ADHD-RS), Screen for Child Anxiety Related Emotional Disorders, and the Children's Depression Inventory...
March 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28346296/antipsychotic-drug-use-in-nursing-home-residents-with-and-without-dementia-keep-an-eye-on-the-pro-re-nata-medication
#7
Katharina Allers, Michael Dörks, Guido Schmiemann, Falk Hoffmann
Behavioral and psychological symptoms of dementia often lead to the prescription of antipsychotics, especially in nursing homes, but their use remains controversial. This study aimed to assess antipsychotic drug use in residents with dementia compared with those without dementia. Data were obtained through the cross-sectional 'inappropriate medication in patients with renal insufficiency in nursing homes' (IMREN) study including data from 21 nursing homes. Descriptive statistics were used and factors associated with the prescription of antipsychotics were identified by logistic regression...
March 24, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28234656/managing-interactions-between-cognitive-enhancers-and-other-psychotropics
#8
Siu W Tang, Wayne H Tang, Brian E Leonard
Polypharmacy is common in psychiatry. Usage of cognitive enhancers is increasing in the psychiatric population. Many clinicians are not familiar with these new psychoactive compounds. This paper reviews the potential drug-drug interactions when these cognitive enhancers are used together with psychotropic drugs and their confounding effects on diagnosis and clinical management.
February 23, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28252452/reduced-sexual-dysfunction-with-aripiprazole-once-monthly-versus-paliperidone-palmitate-results-from-qualify
#9
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Naber
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM 400), a dopamine D2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (PP), a dopamine D2 receptor antagonist, on the Heinrichs-Carpenter Quality-of-Life Scale (QLS) in patients with schizophrenia aged 18-60 years. Sexual dysfunction (Arizona Sexual Experience Scale) and serum prolactin levels were also assessed...
May 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27941358/simvastatin-adjunct-therapy-for-negative-symptoms-of-schizophrenia-a-randomized-double-blind-placebo-controlled-trial
#10
Soode Tajik-Esmaeeli, Ehsan Moazen-Zadeh, Niloofar Abbasi, Seyed V Shariat, Farzin Rezaei, Bahman Salehi, Shahin Akhondzadeh
We investigated the effects of simvastatin adjunctive therapy on the negative symptoms of schizophrenia. In this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4-6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. The Positive and Negative Syndrome Scale was used to measure the negative, positive, and general symptoms of schizophrenia at baseline and every 2 weeks...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27902536/patients-on-psychotropic-medications-and-herbal-supplement-combinations-clinical-considerations
#11
Siu Wa Tang, Wayne Tang, Brian E Leonard
Populations using herbs and herbal preparations are widespread and growing. As many herbal ingredients exert actions on psychotropic drug targets, psychiatrists should be well informed and aware of potential drug-drug interactions in clinical practice. Reliable and clinically useful information in this area, however, is fragmented, if not deficient. This paper reviewed the clinical aspects of herb-drug interactions, focusing in particular on the monoamine oxidase enzyme and P450 cytochrome enzyme-inhibitory properties of herbs and their potential interference with psychotropic drug actions and clinical judgement...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27898432/the-impact-of-paliperidone-palmitate-long-acting-injection-on-hospital-admissions-in-a-mental-health-setting
#12
Nikola Nikolić, Natalie Page, Adil Akram, Maha Khan
We screened 216 patients in a retrospective observational investigator-initiated study, of whom 45.37% patients (n=98) were retained after the inclusion criteria were applied. These patients had been prescribed paliperidone palmitate long-acting injection (PPLAI) with diagnoses of schizophrenia, schizoaffective disorder and bipolar affective disorder. We investigated whether PPLAI has an effect on the frequency and length of admissions to mental health inpatient units, the number of contacts with Crisis Resolution Home Treatment Teams (CRHTT) and frequency of home visits by the CRHTT per patient, over 6 years, split using a 'mirror image' method...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27861191/effects-of-levomilnacipran-extended-release-on-major-depressive-disorder-patients-with-cognitive-impairments-post-hoc-analysis-of-a-phase-iii-study
#13
Keith A Wesnes, Carl Gommoll, Changzheng Chen, Angelo Sambunaris, Roger S McIntyre, Philip D Harvey
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to explore the relationship between cognitive measures, depression symptoms (Montgomery-Åsberg Depression Rating Scale, MADRS), and self-reported psychosocial functioning (Sheehan Disability Scale; SDS). Changes from baseline were analyzed in the intent-to-treat population and subgroups with impaired attention, as indicated by baseline Cognitive Drug Research System scores for Power of Attention and Continuity of Attention...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27824633/a-double-blind-placebo-controlled-study-of-inositol-in-trichotillomania
#14
Eric W Leppink, Sarah A Redden, Jon E Grant
Trichotillomania is characterized by repetitive pulling that causes noticeable hair loss. Data on the pharmacological treatment of trichotillomania are limited, with no clear first-line agent. The aim of the current study was to determine the efficacy and tolerability of inositol in adults with trichotillomania. A total of 38 individuals (35 women; mean age: 28.9±11.4) with trichotillomania entered a 10-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of inositol (dosing ranging from 6 to 18 g/day)...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27755155/is-cerebrovascular-disease-a-silent-condition-in-patients-with-chronic-schizophrenia-related-disorders
#15
Nuria Berrocal-Izquierdo, Miquel Bioque, Miguel Bernardo
Patients with chronic schizophrenia-related disorders are at a heightened risk of developing cardiovascular disease. The presence and interpretation of cerebral vascular lesions in neuroimaging tests in these patients represents a common clinical challenge. Nevertheless, the literature on cerebrovascular disease in this population is scarce and contradictory. The aim of this study was to analyse the relationship between schizophrenia-related disorders and cerebrovascular morbidity. A case-control study compared cerebrovascular morbidity in a group of patients with schizophrenia-related disorder versus a group of patients with another severe mental illness...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27741027/lithium-and-cognition-in-those-with-bipolar-disorder
#16
Amelia Paterson, Gordon Parker
Although a percentage of patients report cognitive side-effects when taking lithium, it can be difficult to determine from the literature whether any cognitive changes reflect lithium itself, the lithium serum level, residual mood symptoms, the underlying nature of bipolar disorder, or biological alterations such as hypothyroidism. This review was carried out to synthesize and evaluate relevant literature examining any cognitive impact of lithium in those with bipolar disorder. The effect of lithium in those with bipolar disorder was examined across the cognitive domains of attention, psychomotor speed, processing speed, working memory, intellectual functioning, verbal memory, visual memory, and executive functioning by reviewing the published empirical literature...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27685179/adverse-events-in-children-and-adolescents-treated-with-quetiapine-an-analysis-of-adverse-drug-reaction-reports-from-the-danish-medicines-agency-database
#17
Klaus D Jakobsen, Helle Wallach-Kildemoes, Christina H Bruhn, Nasseh Hashemi, Anne K Pagsberg, Anders Fink-Jensen, Jimmi Nielsen
Quetiapine is a low-affinity dopamine D2 receptor antagonist, approved for the treatment of bipolar disorder and schizophrenia in children and adolescents by the Food and Drug Administration, but not by European Medicine Agency. Although knowledge of adverse drug reactions in children and adolescents is scarce, quetiapine is increasingly being used for youth in Denmark. The aim of this case study is to discuss adverse drug events (ADEs) spontaneously reported to the Danish Medicines Agency on quetiapine used in the pediatric population in relation to adversive drug reactions (ADRs) reported in the European Summary of Product Characteristics (SPCs)...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28225439/tachycardia-in-patients-treated-with-clozapine-versus-antipsychotic-long-acting-injections
#18
Björn M Nilsson, Oscar Edström, Leif Lindström, Petter Wernegren, Robert Bodén
Tachycardia is a known adverse effect during clozapine treatment. However, prevalence reported differs widely between studies and hitherto there are no studies comparing clozapine-treated patients with a similar control group. The present study was carried out to assess the prevalence of tachycardia in patients treated with clozapine and antipsychotic long-acting injections (LAI). Data on heart rate (HR), concomitant medication, and relevant anthropometric and laboratory measurements were collected for all clozapine-treated patients (n=174) in a defined catchment area and compared with data on patients treated with LAI (n=87)...
February 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28207568/predictors-of-rehospitalization-in-a-naturalistic-cohort-of-patients-with-bipolar-affective-disorder
#19
Maria O'Hagan, Victoria Cornelius, Allan H Young, David Taylor
There has only been limited research into the predictors of readmission in bipolar disorder. We carried out a 1-year follow-up of patients discharged from a single mental health unit following admission for treatment of an acute bipolar episode. Of 519 patients followed up for 1 year, 167 (32.2%) were readmitted. There was no association between readmission and any drug regimen. Prescription of antidepressants at discharge was not associated with increased risk of readmission [odds ratio (OR): 0.99, 95% confidence interval (CI): 0...
February 15, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28181959/indications-for-and-use-of-long-acting-injectable-antipsychotics-consideration-from-an-inpatient-setting
#20
Taishiro Kishimoto, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane
Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed...
February 8, 2017: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"